56 Results for "

epilepsy model

" in MedChemExpress (MCE) Product Catalog:
Products (56)

56 Results for "epilepsy model" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-107661
CAS No.: 185517-21-9
Purity:  ≥98.0%
Synonyms: ONO-2506; (R)-2-Propyloctanoic acid
Target:  

ERK Akt NF-κB EAAT

Arundic Acid is an orally effective astrocyte function modulator and neuroprotective agent. Arundic Acid increases the expression and function of the astrocytic glutamate transporter EAAT1 by activating the ERK, Akt and NF-κB pathways. Arundic Acid attenuates retinal ganglion cell death in a normal-tension glaucoma model. Arundic Acid exerts neuroprotective effects in a mouse model of Parkinson's disease. Arundic Acid is a S100β protein synthesis inhibitor that prevents neurological deficits and brain tissue damage after intracerebral hemorrhage in rats. Arundic Acid downregulates neuroinflammation and astrocytic dysfunction after status epilepticus in immature rats. Arundic Acid is applicable to research related to Parkinson's disease, cerebral ischemia, glaucoma, intracerebral hemorrhage and epilepsy .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-109009
CAS No.: 1294000-61-5
Purity:  99.65%
Synonyms: UCB-0942
Target:  

GABA Receptor

Research Areas:  

Neurological Disease

Padsevonil (UCB0942) is a potent antiepileptic agent that selectively acts on presynaptic and postsynaptic targets. Padsevonil binds to synaptic vesicular protein 2 (SV2) with high affinity. Padsevonil is also a positive allosteric modulator and partial agonist of GABAAR, with high potency against α1 and α5 receptors. Padsevonil has antiepileptic effects in a variety of rodent models .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-110192
CAS No.: 1443246-62-5
Purity:  99.14%
Synonyms: VU 0456810; CID 56642816
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

ML 297 (VU 0456810) is a potent and selective GIRK1/2 activator, with an EC50 of 0.16 μM. ML 297 can cross the blood-brain barrier with brain-to-plasma ratio of 0.2 in mice model (i.p.). ML 297 is potential for the treatment of epilepsy .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-120546
CAS No.: 1199236-64-0
Purity:  98.73%
Synonyms: Z944; PRAX-944
Ulixacaltamide (Z944) is an orally available T-type calcium channel antagonist that can slow the progression of epilepsy. Ulixacaltamide effectively reduces tremor in a normal alkaline tremor animal model. Ulixacaltamide reverses thermal hyperalgesia and mediates pain relief .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-111751
CAS No.: 2035814-50-5
Purity:  99.18%
Target:  

iGluR

Research Areas:  

Neurological Disease

JNJ-61432059 is a blood-brain barrier-permeable, orally active TARP γ-8-associated AMPAR modulator with anticonvulsant activity. JNJ-61432059 negatively regulates GluA1 and positively modulates GluA2-containing AMPARs. JNJ-61432059 exerts potent protective effects in rodent epilepsy models. JNJ-61432059 is applicable for epilepsy-related research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-14948
CAS No.: 194085-75-1
Purity:  99.77%
Synonyms: RWJ-333369
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

Carisbamate (RWJ-333369) is an orally active neuromodulator. Carisbamate prevents the development and production of epilep-like discharges and has a neuroprotective effect after in vitro epilepticus-like injury. Carisbamate has good antiepileptic activity in genetic models of generalized and nonconvulsive epilepsy .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-W017370
CAS No.: 99-48-9
Carveol is an orally active monoterpenoid alcohol with neuroprotective, antioxidant, anti-inflammatory, anticonvulsant, antidiabetic, hypolipidemic and hepatoprotective activities. Carveol upregulates the expression of Bcl2, downregulates the expression of caspase-3, TNF-α, IL1β and IL6, activates the Nrf2/HO-1 antioxidant signaling pathway, inhibits the RAGE/NF-κB signaling pathway, and suppresses neuroinflammation and neuronal apoptosis. Carveol inhibits α-synuclein aggregation, improves cognitive ability, and inhibits α-amylase activity. Carveol exerts neuroprotective effects in a rat model of Parkinson's disease. Carveol exhibits antidiabetic effects in alloxan-induced diabetic rats. Carveol alleviates PTZ-induced seizures in rats. Carveol can be used in research related to Parkinson's disease, epilepsy, diabetes and ischemic stroke .
loading...
    loading...
Cat. No.: HY-B0340
CAS No.: 77191-36-7
Synonyms: DM9384; DZL-221
Nefiracetam is a cognition-enhancing agent. Nefiracetam is an activator of nAChR, N-methyl-D-aspartate receptor (NMDAR), mGluR5, PKC, gamma-aminobutyric acid (GABA), and N/L-type Ca 2+ channels. Nefiracetam promotes neuroplasticity and enhances neuroprotection. Nefiracetam can be used in Alzheimer's disease, epilepsy, and cerebral ischemia research .
loading...
    loading...
Cat. No.: HY-160955
CAS No.: 1223877-07-3
Target:  

Phosphatase

Research Areas:  

Neurological Disease

Z218484536 is a selective and brain-penetrant phosphoserine phosphatase (PSPH) inhibitor. Z218484536 binds to PSPH with a Kd value of approximately 0.23 μM. Z218484536 reduces L-serine and D-serine levels in astrocytes. Z218484536 is able to suppress spontaneous epileptic seizures without causing serious side effects. Z218484536 also shows good anti-epileptic effects in the temporal lobe epilepsy (TLE) model .
loading...
    loading...
Cat. No.: HY-107482
CAS No.: 34562-97-5
Purity:  98.25%
Synonyms: Nicotinoyl-GABA; Nicotinoyl-γ-aminobutyric acid
Target:  

GABA Receptor

Research Areas:  

Neurological Disease

Picamilon is an orally active derivative of γ-aminobutyric acid that has nootropic effect. Picamilon improves the epilepsy model in rats and promotes correction of functional disorders of the pancreas during Alloxan (HY-W017227)-induced diabetes mellitus in rats .
loading...
    loading...
Cat. No.: HY-138668
CAS No.: 2763378-71-6
Purity:  99.05%
Target:  

TRP Channel

Research Areas:  

Neurological Disease

JW-65 is a selective TRPC3 channel inhibitor with favorable blood-brain barrier penetration. JW-65 directly binds to human TRPC3 protein and modulates calcium signaling to reduce seizure susceptibility. JW-65 reduces seizure incidence, severity, and duration while prolonging seizure latency in multiple seizure models. JW-65 alleviates Aβ‑induced neuronal damage. JW-65 serves as a valuable tool for research on epilepsy, seizure disorders, and Alzheimer’s disease .
loading...
    loading...
Cat. No.: HY-W010178
CAS No.: 54947-74-9
4-Methyloctanoic acid is an endogenous branched-chain medium-chain fatty acid and a negative regulator of the cAMP/PKA signaling pathway. 4-Methyloctanoic acid exerts antiepileptic effects by inhibiting epileptiform discharges and terminating behavioral and electroencephalographic seizures. 4-Methyloctanoic acid has neuroprotective effects; its polar metabolites can cross the blood-brain barrier, repair presynaptic release defects, improve motor function and alleviate neuromuscular degeneration in ALS models. 4-Methyloctanoic acid regulates phosphatidylinositol metabolism, reduces PIP/PIP2 levels and increases inositol levels. 4-Methyloctanoic acid can be used in studies related to epilepsy and amyotrophic lateral sclerosis .
loading...
    loading...
Cat. No.: HY-175668
CAS No.: 2756581-81-2
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

IDOR-1104-0086 is an orally active Kv7 potassium channel opener with an EC50 of 210 nM that can cross blood-brain barrier. IDOR-1104-0086 displays strong selectivity against the hERG channel with an IC20 of 25 μM. IDOR-1104-0086 exhibits efficacy in two rodent models of epilepsy and a favorable tolerability profile. IDOR-1104-0086 can used for the study of epilepsy .
loading...
    loading...
Cat. No.: HY-155811
CAS No.: 2377187-09-0
Purity:  99.85%
Target:  

iGluR

Research Areas:  

Neurological Disease

DQP-997-74 (compound 2i) is a selective negative allosteric modulator of N-methyl-d-aspartate receptor (NMDAR), specifically targeting GluN2C/D (IC50: 0.069 μM and 0.035 μM), with blood-brain barrier penetrability. Where DQP refers to dihydroquinoline-pyrazoline. DQP-997-74 acts synergistically with the agonist glutamate to exhibit time-dependent enhanced potency in inhibiting hypersynchronous activity driven by high-frequency excitatory synaptic transmission. DQP-997-74 reduces the number of epileptogenesis in a murine model of tuberous sclerosis complex (TSC)-induced epilepsy. DQP-997-74 can be used for research on NMDAR-related neurological diseases .
loading...
    loading...
Cat. No.: HY-W012481
CAS No.: 631-07-2
Synonyms: Ethylphenylhydantoin; Phenylethyihydantoin; Desmethylmephenytoin
Target:  

Drug Metabolite

Research Areas:  

Neurological Disease

Nirvanol (Ethylphenylhydantoin) is a metabolite of Mephenytoin (HY-B1184) that exerts anticonvulsant effects in the maximal electroshock (M.E.S.) seizure model in mice. Nirvanol shows potential for research in epilepsy-related neurological disorders .
loading...
    loading...
Cat. No.: HY-103232
CAS No.: 258282-23-4
Target:  

mGluR

Research Areas:  

Neurological Disease

IEM-1925 bromide is an orally active glutamate receptor antagonist, increases the latent period and decreases the duration of status epilepticus in rats in a lithium-pilocarpine model of epilepsy .
loading...
    loading...
Cat. No.: HY-109009A
CAS No.: 1294001-37-8
Synonyms: (S)-UCB-0942
Target:  

GABA Receptor

Research Areas:  

Neurological Disease

(S)-Padsevonil is the S-enantiomer of Padsevonil (HY-109009).Padsevonil (UCB0942) is a potent antiepileptic agent that selectively acts on presynaptic and postsynaptic targets. Padsevonil binds to synaptic vesicular protein 2 (SV2) with high affinity. Padsevonil is also a positive allosteric modulator and partial agonist of GABAAR, with high potency against α1 and α5 receptors. Padsevonil has antiepileptic effects in a variety of rodent models .
loading...
    loading...
Cat. No.: HY-107482A
CAS No.: 62936-56-5
Synonyms: Nicotinoyl-GABA sodium; Nicotinoyl-γ-aminobutyric acid sodium; Sodium 4-(nicotinamido)butanoate
Target:  

GABA Receptor

Research Areas:  

Neurological Disease

Picamilon sodium is an orally active derivative of γ-aminobutyric acid that has nootropic effect. Picamilon sodium improves the epilepsy model in rats and promotes correction of functional disorders of the pancreas during Alloxan (HY-W017227)-induced diabetes mellitus in rats .
loading...
    loading...
Cat. No.: HY-118160
CAS No.: 65240-86-0
Synonyms: NSC 73233
PPM-18 (NSC 73233) is a Vitamin K (HY-B2172) analog. PPM-18 prevents LPS-induced IκBα degradation, thereby inhibiting NF-κB activation and nuclear translocation of NF-κB. PPM-18 inhibits LPS-induced nitrite production and iNOS expression. PPM-18 inhibits HDAC6. PPM-18 induces ROS accumulation, activates AMPK, inhibits the mTORC1 and PI3K/AKT pathways, initiates Autophagy, and induces Apoptosis. PPM-18 suppresses seizures in zebrafish and mouse epilepsy models. PPM-18 prevents LPS-induced lethal toxicity and delayed hypotension. PPM-18 exhibits anticancer activity against leukemia and bladder cancer. PPM-18 can be used in research related to septic shock, bladder cancer and atherosclerosis .
loading...
    loading...
Cat. No.: HY-155238
CAS No.: 1520073-91-9
Target:  

GABA Receptor

Research Areas:  

Neurological Disease

E2730 is a noncompetitive but selective inhibitor of gamma-aminobutyric acid (GABA) transporter 1 (GAT1) with orally available and antiepileptic activity. E2730-mediated GAT1 inhibition is positively correlated with environmental GABA levels and selectively inhibits GAT1-mediated GABA uptake. E2730 (5-50 mg/kg; po) in rat amygdala ignition model, and in mouse cornea ignition (5-50 mg/kg), drug resistance 6Hz-44mA has demonstrated in vivo efficacy in models of psychomotor epilepsy (5-50 mg/kg), fragile X syndrome (2.5-300 mg/kg), and Dravet syndrome (10 mg/kg, 20 mg/kg) .
loading...
    loading...